TOM MURPHY, AP Business Writer A potential GlaxoSmithKline heart disease treatment acquired in a key company takeover fell short in a big, late-stage study. The British drugmaker said Tuesday that the treatment, darapladib, failed to produce a statistically significant reduction in major cardiovascular events like heart attacks, strokes or death when added to a patient’s […]
